-
Regeneron v. Amgen: Patent Infringement and Biologic Formulations
On March 14, 2025, the United States Court of Appeals for the Federal Circuit issued a decision in Regeneron Pharmaceuticals, Inc. v. Amgen Inc., affirming the district court’s…
4 min read
-
In re Xencor: Written Description and Preamble Limitations
On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision in In re Xencor, Inc., affirming the rejection of Xencor’s patent…
4 min read
-
Merck v. Aurobindo: Patent Term Extensions and Reissued Patents
Introduction The Federal Circuit recently issued a significant ruling in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., clarifying how patent term extensions (PTEs) apply to…
4 min read
-
Trademark Showdown: Bullshine Distillery v. Sazerac Brands and the FIREBALL Controversy
On March 12, 2025, the Federal Circuit handed down its decision in Bullshine Distillery LLC v. Sazerac Brands, LLC, a case that highlights fundamental principles in trademark law,…
4 min read
-
Sierra Wireless v. Sisvel: (Dis)Qualification of Expert Witnesses in the PTAB
In its March 10, 2025 decision in Sierra Wireless, ULC v. Sisvel S.p.A., the Federal Circuit vacated a Patent Trial and Appeal Board (PTAB) decision due, in part,…
4 min read
-
Federal Circuit Vacates PTAB Decision in CQV Co. v. Merck Patent GmbH, Raising Key Issues in Patent Infringement and Prior Art Analysis
The United States Court of Appeals for the Federal Circuit recently issued an opinion in CQV Co., Ltd. v. Merck Patent GmbH, vacating and remanding the Patent Trial…
4 min read
